Department of Biomedical Engineering, Washington University in St. Louis, St. Louis, MO, USA.
Clinical Science, Profound Medical Inc., Mississauga, ON, Canada.
Int J Hyperthermia. 2019;36(1):1147-1159. doi: 10.1080/02656736.2019.1685684.
To evaluate the feasibility and assess safety parameters of magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU)-mediated hyperthermia (HT; heating to 40-45 °C) in various pelvic targets in a porcine model . Thirteen HT treatments were performed in six pigs with a commercial MRgHIFU system (Sonalleve V2, Profound Medical Inc., Mississauga, Canada) to muscle adjacent to the ventral/dorsal bladder wall and uterus to administer 42 °C (±1°) for 30 min (±5%) using an 18-mm target diameter and 100 W power. Feasibility was assessed using accuracy, uniformity, and MR-thermometry performance-based metrics. Safety parameters were assessed for tissues in the targets and beam-path by contrast-enhanced MRI, gross-pathology and histopathology. Across all HT sessions, the mean difference between average temperature (T) and the target temperature within the target region-of-interest (tROI, the cross-section of the heated volume at focal depth) was 0.51 ± 0.33 °C. Within the tROI, the temperature standard deviation averaged 1.55 ± 0.31 °C, the average 30-min T variation was 0.80 ± 0.17 °C, and the maximum difference between T and the 10th- or 90th-percentile temperature averaged 2.01 ± 0.44 °C. The average time to reach ≥41 °C and cool to ≤40 °C within the tROI at the beginning and end of treatment was 47.25 ± 27.47 s and 66.37 ± 62.68 s, respectively. Compared to unheated controls, no abnormally-perfused tissue or permanent damage was evident in the MR images, gross pathology or histological analysis. MRgHIFU-mediated HT is feasible and safety assessment is satisfactory for treating an array of clinically-mimicking pelvic geometries in a porcine model , implying the technique may have utility in treating pelvic targets in human patients.
评估磁共振引导高强度聚焦超声(MRgHIFU)介导的热疗(HT;加热至 40-45°C)在猪模型中各种盆腔靶标中的可行性,并评估安全性参数。使用商业 MRgHIFU 系统(加拿大密西沙加市 Profound Medical Inc. 的 Sonalleve V2)在 6 头猪中进行了 13 次 HT 治疗,将肌肉与腹/背侧膀胱壁和子宫相邻,将 42°C(±1°C)施加 30 分钟(±5%),使用 18-mm 靶直径和 100 W 功率。使用基于准确性、均匀性和磁共振测温性能的指标来评估可行性。通过对比增强 MRI、大体病理学和组织病理学评估靶标和射束路径中的组织安全性参数。在所有 HT 治疗中,目标区域内平均温度(T)与目标温度之间的平均差异为 0.51±0.33°C。在 tROI 内,温度标准差平均为 1.55±0.31°C,平均 30 分钟 T 变化为 0.80±0.17°C,T 与第 10 或 90 百分位数温度之间的最大差异平均为 2.01±0.44°C。在治疗开始和结束时,tROI 内达到≥41°C 并冷却至≤40°C 的平均时间分别为 47.25±27.47s 和 66.37±62.68s。与未加热的对照组相比,MR 图像、大体病理学或组织学分析均未显示异常灌注组织或永久性损伤。MRgHIFU 介导的 HT 是可行的,安全性评估令人满意,可用于治疗猪模型中一系列临床模拟的盆腔几何形状,这意味着该技术可能在治疗人类患者的盆腔靶标方面具有应用价值。